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A B S T R A C T
Purpose
We examined the feasibility of using CYP2D6 genotyping to determine optimal tamoxifen dose
and investigated whether the key active tamoxifen metabolite, endoxifen, could be increased by
genotype-guided tamoxifen dosing in patients with intermediate CYP2D6 metabolism.
Patients and Methods
One hundred nineteen patients on tamoxifen 20 mg daily  4 months and not on any strong
CYP2D6 inhibiting medications were assayed for CYP2D6 genotype and plasma tamoxifen
metabolite concentrations. Patients found to be CYP2D6 extensive metabolizers (EM) remained
on 20 mg and those found to be intermediate (IM) or poor (PM) metabolizers were increased to
40 mg daily. Eighty-nine evaluable patients had tamoxifen metabolite measurements repeated 4
months later.
Results
As expected, the median baseline endoxifen concentration was higher in EM (34.3 ng/mL)
compared with either IM (18.5 ng/mL; P  .0045) or PM (4.2 ng/mL; P  .001). When the dose
was increased from 20 mg to 40 mg in IM and PM patients, the endoxifen concentration rose
significantly; in IM there was a median intrapatient change from baseline of 7.6 ng/mL (0.6 to
23.9; P  .001), and in PM there was a change of 6.1 ng/mL (2.6 to 12.5; P  .020). After the
dose increase, there was no longer a significant difference in endoxifen concentrations between
EM and IM patients (P  .84); however, the PM endoxifen concentration was still signifi-
cantly lower.
Conclusion
This study demonstrates the feasibility of genotype-driven tamoxifen dosing and demonstrates
that doubling the tamoxifen dose can increase endoxifen concentrations in IM and PM patients.
J Clin Oncol 29:3232-3239. © 2011 by American Society of Clinical Oncology
INTRODUCTION
Approximately 80% of the 182,000 invasive breast
cancers diagnosed this year in the United States
will be endocrine receptor–positive appropriate
for tamoxifen treatment.1 Tamoxifen is a prod-
rug, and may need to be metabolized to be active;
up to half of those taking it may not receive the full
benefit because of genetic differences that limit this
metabolism.2 Tamoxifen is metabolized to the anti-
estrogen 4-hydroxytamoxifen by several enzymes.
However, a preferred route is the formation of the
intermediate metabolite N-desmethyltamoxifen
by cytochrome P450 3A4/5 with cytochrome
P450 2D6 (CYP2D6) further metabolizing N-
desmethyltamoxifen to the most abundant active
metabolite, endoxifen (Fig 2).3-5 Endoxifen and
4-hydroxytamoxifen have a 50-fold higher affinity
for the estrogen receptor (ER) than tamoxifen, and
the plasma concentration of endoxifen is 5 to 10
times higher than 4-hydroxytamoxifen; for this rea-
son endoxifen is considered the major active metab-
olite.6,7 Multiple studies examining endoxifen in ER
binding and inhibition of estrogen-induced cell pro-
liferation demonstrate that endoxifen is a highly ac-
tive metabolite of tamoxifen.6,8,9
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Over 75 reduced-activity alleles of CYP2D6 have been de-
tected that vary in ability to convert tamoxifen to endoxifen. In
previous CYP2D6 studies, approximately 50% of women were
extensive metabolizers (EM; active CYP2D6), 43% were interme-
diate metabolizers (IM; reduced but not inactive CYP2D6), and
7% were poor metabolizers (PM, inactive CYP2D6).10 CYP2D6
genetic variation affects endoxifen concentrations.7,11
Some, but not all,12-19 of the initial studies showed worse
disease-free survival (DFS) for tamoxifen-treated patients with
breast cancer with CYP2D6 dysfunctional alleles,20-32 or those who
were taking CYP2D6-interacting medications.24,27,33,34 However,
two large studies showed no association between CYP2D6 geno-
type and outcome, which has raised concern about CYP2D6 as a
tamoxifen efficacy biomarker.35,36
Tamoxifen is US Food and Drug Administration approved at
both 20 mg and 40 mg per day, and has been used safely and
effectively at both doses.37,38 It is unknown what effect changing
tamoxifen dose might have on endoxifen concentrations in a dys-
functional allele population.
Modern technologic advances aiding in therapeutic decision
making include pharmacogenomic assays to identify patient-based
factors in drug metabolism. In addition to using these assays to choose
among drugs, it is possible that they can help optimize drug dosing. In
this study, we examined the feasibility and impact of using CYP2D6
genotyping to determine tamoxifen dose and demonstrated that en-




Women ( 18 years old) were eligible if they were on tamoxifen 20 mg
daily for at least 4 months (ensuring steady-state concentrations), nonpreg-
nant/nonlactating, had an Eastern Cooperative Oncology Group performance
status of 0 to 2, normal kidney, liver, and bone marrow function. Patients were
excluded if they had a history of thromboembolic disease, prior liver or bone
marrow transplant, or had received blood product transfusions within the past
3 months. Concurrent medication therapy with medications known to
inhibit CYP2D6 was not permitted (ie, buproprion, amiodarone, haloper-
idol, indinavir, ritonavir, quinidine, duloxetine, paroxetine, or fluoxetine).
The protocol was approved at each respective institutional review board
and all participants provided written informed consent.
CYP2D6 Genotyping
CYP2D6 genotyping was performed in a Clinical Laboratory Improved
Amendments–certified clinical laboratory using the AmpliChip CYP450 test
(Roche Diagnostics, Indianapolis, IN) for the major CYP2D6 alleles (Data
Supplement). The turnaround time for the CYP2D6 genotyping was 1 to 2
weeks to patient and physician notification of their genotype group.
Intervention
After enrollment, participants underwent phlebotomy to obtain speci-
mens for CYP2D6 genotype and tamoxifen metabolite assessment (Fig 1). For
dosing purposes, patients were classified as EM, IM, or PM based on their
respective genotypes. Patients with two CYP2D6 alleles with normal metabolic
activity (EM/EM) were considered to be EM and were instructed to remain on
their dose of tamoxifen 20 mg daily, as was one patient with an ultrarapid
metabolism allele. Patients with one or more CYP2D6 alleles with reduced
Women receiving tamoxifen ≥ 4 months
Repeat blood for tamoxifen metabolite concentrations in 4 months, QOL analyses
EM
(n = 32)
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Fig 1. CONSORT diagram. EM, exten-
sive metabolizers; IM, intermediate me-
tabolizers; PM, poor metabolizers; QOL,
quality of life.
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enzymatic activity or heterozygous for an inactive allele were considered IM
(EM/IM, EM/PM, IM/IM, IM/PM); those with two inactive alleles were con-
sidered PM (PM/PM). Patients with IM or PM genotypes were instructed to
increase their tamoxifen to 40 mg daily (given as 20 mg twice daily). Adherence
to therapy was recorded via a self-reported pill diary. Quality of life (QOL)
assessment (including hot flashes) was performed using the Functional Assess-
ment of Cancer Therapy Endocrine Subscale (FACT-B [es]) and the Breast
Cancer Prevention Trial Menopausal Symptom Scale (BCPT-MSS) at time of
study consent.39,40 After 4 months  4 weeks of genotype directed therapy,
tamoxifen metabolite concentrations were repeated and toxicity and QOL
measures were assessed using the National Cancer Institute Common Toxicity
Criteria for Adverse Events, version 3.0 and the FACT- B (es) and BCPT-MSS.
At the end of protocol-directed therapy, the nature of further endocrine
therapy was at the discretion of the patient and treating physician.
Tamoxifen and Metabolite Measurement in Plasma
Tamoxifen and its metabolites were measured by liquid chromatography
tandem mass spectrometry (LC-MS/MS). Standard curves and quality con-
trols were run with each sample batch. The intraday coefficient of variance was
lower than 10% for all compounds, while the interday was lower than 15%. An
intrapatient assay was not run for each sample set, but repeated measurement
was performed in a subset of samples. The results show that the intrasample
variability was lower than 10%. The Data Supplement details a full description
of this method.
Statistical Methods
The primary objective was to evaluate change in plasma endoxifen con-
centrations after an increase in tamoxifen dose from 20 mg to 40 mg among
patients with IM CYP2D6 genotypes. Endoxifen concentrations were mea-
sured at baseline and after 4 months on tamoxifen. A one-sample Wilcoxon
test was used to test the null hypothesis that the change in endoxifen concen-
tration from baseline equals zero. Pair-wise two-sample Wilcoxon rank sum
test was used to test the difference in endoxifen concentration among the three
genotype groups (EM, IM, and PM). We posited that a potentially clinically
meaningful end point would be to achieve the same endoxifen concentration
in IM patients on a higher tamoxifen dose as EM patients on 20 mg per day.
Assuming that endoxifen concentrations are 40% higher in EM than IM
patients,7,11 12% nonevaluability, a two-sided significance level of .05, and a
sample size of 40 patients with IM CYP2D6 genotypes, 100 patients would
provide 84% power.41 Actual enrollment was 119 because at the time of
accrual completion 19 patients were in equal stages of screening. The tests were
repeated for tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and for
the endoxifen/N-desmethlytamoxifen ratio. The Data Supplement details the
generalized estimating equation (GEE) method.
Patient responses to the survey questions in the FACT-B (es) and BCPT-
MSS at baseline and 4 months after the treatment were reported. A propor-
tional odds model being fit with the GEE method42 was used to evaluate the
changes in response over the two time points and for the three genotype
groups. The outcome scores used are in an ordinal scale, ranging from 0 “not at
all” to 4 “very much.”
Unless noted, Fisher’s exact test was used to evaluate baseline character-
istic differences between genotype groups. All analyses were performed using
SAS statistical software, version 9.2 (SAS Institute Inc, Cary, NC).
RESULTS
Patients and Genotyping
A total of 119 patients were enrolled in this study; one withdrew
consent immediately after registration, one had an allele of unknown
significance (CYP2D6*25) and was excluded from endoxifen concen-
tration analyses, and 28 withdrew before having their 4-month metab-
olite concentrations drawn, leaving 89 patients for the analysis of the
tamoxifen dose intervention (Table 1; Fig 1). Table 2 presents the
CYP2D6 allele frequencies from our population. A higher than ex-
pected proportion of patients (72%) had at least one PM or IM allele.
The odds of an African American having a CYP2D6 allele consistent
withreducedmetabolismwereabouttwotimeshigherthanthoseinother
(mostly white) patients (odds ratio [OR], 2.26; 95% CI, 1.17 to 4.37).
Adherence to Protocol
For the patients completing protocol-directed therapy, 51% (45
of 89) did not report missing any tamoxifen doses. Of those that




































Fig 2. Pathways of tamoxifen and the main
CYP enzymes. Concept adapted from Goetz
et al.5
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doses. Overall, 93% (83 of 89) reported missing 10 or fewer doses over
the 4-month period. Six patients (six of 89; 7%) reported missing 12 to
27 doses. The Data Supplement shows reported adherence by geno-
type group.
Endoxifen Concentrations
The results are summarized in Table 3. In the univariate analysis
the median baseline endoxifen concentration was significantly higher
in the EM patients compared with either IM (46% higher; P  .0045),
or PM (88% higher; P  .001) patients, and the median endoxifen
concentration in PM was 77% lower than in IM (P  .0006). Thus, as
expected, there was a statistically significant baseline difference among
the underlying distributions in the three genotype groups. There was
no statistical difference between baseline endoxifen concentrations
and concentrations 4 months later among the EM group (tamoxifen
20 mg/day; P  .25). The tamoxifen dose increase from 20 mg to 40
mg resulted in a significant rise in endoxifen concentrations in both
IM (P  .001) and PM (P  .020) patients. After 4 months, there was
no significant difference in median endoxifen concentrations between
EM taking 20 mg and IM taking 40 mg (P  .84) even though the
baseline median endoxifen concentration was almost twice as great for
the EM than for the IM group. The median endoxifen concentration
in the PM group was still significantly lower than in the EM (P  .016)
and IM (P  .019) groups (Figs 3A and 3B, 3C, 3D). Based on three
multiple comparisons, the Bonferroni P value is .017. The Data Sup-
plement shows the results of the IM patients split into EM/IM, IM/IM,
Table 1. Baseline Characteristics (n  89), Grouped by CYP2D6 Metabolism Phenotype, and No. of Patients With Each CYP2D6 Combination Grouped by CYP2D6
Metabolism Phenotype (n  89)
Characteristic EM (n  29) IM (n  51) PM (n  9) P
Median age, years 49 49 47 .587
Range 35-77 35-72 36-56
Race/ethnicity .738
White 22 40 6
African American 4 9 3
Asian 1 2 —
Hispanic 2 — —
Median tamoxifen duration, years 0.7 1.3 1.0 .055
Range 0.3-4.4 0.3-5.0 0.5-3.0
Menopause .892
Pre/peri 16 30 4
Post 13 21 5
SSRI/SNRI use .489
Total 5 16 1
Citalopram 3 4 —
Venlafaxine 1 9 1
Escitalopram 1 3 —
Reason on tamoxifen .07
Invasive carcinoma 28 41 9
DCIS 1 10 —
Prior chemotherapy .041
Yes 22 27 8
No 7 24 1
EM EM/UM  1; 1.1%
EM/EM  28; 31.5%
IM EM/IM  20; 22.5%
EM/PM  19; 21.3%
IM/IM  4; 4.5%
IM/PM  8; 9.0%
PM PM/PM  9; 10.1%
Abbreviations: DCIS, ductal carcinoma in situ; EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer; SNRI, serotonin-norepinephrine
reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.
The Kruskal-Wallis test was used to test the shift of location from the median value.






Other1, 2 35 9 10 17 29 41
Total patients (n  118) 0.48 0.02 0.25 0.02 0.03 0.04 0.02 0.13 .02
African American patients (n  25) 0.32 0 0.22 0 0 0.18 0.08 0.14 .06
Non-African American patients (n  93) 0.53 0.02 0.25 0.02 0.03 0.01 0 0.13 .01
Abbreviations: EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer.
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IM/PM, and EM/PM. Median endoxifen concentrations increased
within all IM subsets (significant for EM/IM and EM/PM). Splitting
these groups did not explain the interpatient variability seen in re-
sponse to the tamoxifen dose increase, although the numbers in each
subset are small.
In order to address the pattern of change in median endoxifen
concentration from baseline, the GEE approach was used for the
repeated measurements analyses. The results suggested that the IM
group had a significant increase (7.6 ng/mL; P .0062) in endoxifen
concentration from baseline to 4 months later when compared to the
Table 3. Median Endoxifen Concentrations for the Three CYP2D6 Genotype Groups and Change Over Time (EM patients no change in dose; IM and PM



















EM 32 34.9 29 34.3 29.2 1.5 28 to 11.2 .25
IM 74 19.8 51 18.5 21.8 7.6 0.6 to 23.9  .001
PM 11 4.6 9 4.2 12.9 6.1 2.6 to 12.5 .020
Abbreviations: EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer.
Medians of the three groups are significantly different from each other with EM v IM: P  .0054; EM v PM: P  .001; IM v PM: P  .001.
†Represents aggregate data within genotype groups, not intrapatient data.
‡Relates to the median intrapatient change from baseline.
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Fig 3. Endoxifen concentration (ng/mL) change over time, demonstrating (A) no significant difference in extensive metabolizers (EM; P  .25; no dose change); (B) a significant
increase (P  .001) in endoxifen after 4 months of increased tamoxifen in intermediate metabolizers (IM); and (C) a significant increase (P  .020) in endoxifen after 4 months of
increased tamoxifen in poor metabolizers (PM), although still lower than other groups. (D) Box and whisker plot of change over time of endoxifen concentration by genotype group
(EM, IM, PM), demonstrating an increase in endoxifen concentration in the groups with increased dose (IM, PM; P  .001 and P  .020, respectively). The two ends of the boxes
indicate the upper and lower quartiles, the median is the middle line, the mean is the hollow square within the boxes, and the whiskers represent the upper and lower fence of the
data. Observations outside the fences are identified as outliers with a square. The EM/ultrarapid metabolizer (UM) patient’s value lies within the ends of the boxes (between the upper
and lower quartiles) for the EM group (change of 17 ng/mL). (A) Value outside the figure for baseline  126 ng/mL. The EM/UM patient had a baseline endoxifen concentration of
37 ng/mL and a 4-month concentration of 20 ng/mL. (B) Value outside range of figure for 4 months  170 ng/mL and value outside figure for baseline  141 ng/mL.
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EM group (Fig 4). There was also a convergence of IM and EM with
the former increasing significantly and a nonsignificant but numerical
decrease in the latter. While the majority of EM patients had no
notable change in endoxifen concentration, eight patients had a
marked decrease that is poorly understood (all reported complete
adherence). Eight EM patients had 4-month endoxifen concentra-
tions lower than 20 ng/mL (comparable to PM, six reporting complete
adherence). Five EM patients had baseline endoxifen concentrations
lower than 20 ng/mL that increased at 4 months (no prestudy adher-
ence data was obtained). As anticipated, an increase in dose for the PM
resulted in a significant pattern of change (P  .0035) in median endox-
ifen concentration when compared to EM, but not between IM and PM.
The data for tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen
concentrations, and the endoxifen/N-desmethyltamoxifen ratio are lo-
cated in the Data Supplement.
Toxicity/QOL
No thromboembolic events were seen. There was one episode of
grade 3 vaginal bleeding (IM patient, 1 month into the double dose,
endometrialbiopsynegativeforcarcinoma).Allotheradverseeventswere
lower than grade 3, including the three other reasons for withdrawal (ie,
nausea, cramping, joint aches). There was no evidence of a difference of
meanhotflashscoresamonggroupsatbaseline(EM,2.3;IM,1.9;PM,2.5;
P  .18), or at 4 months (EM, 1.9; IM, 1.9; PM, 2.3; P  .71), or over
time irrespective of dose (Data Supplement). The other measured
endocrine symptoms for the FACT-B (es) and the BCPT-MSS are
described in the Data Supplement, and with few exceptions, do not
show a difference between genotype groups or between patients
who received different doses of tamoxifen (based on 180 multiple
comparisons, the Bonferroni P value is .00028). There were no
associations between hot flashes and endoxifen concentrations at
baseline (P  .97) or at 4 months (P  .14; Data Supplement).
DISCUSSION
This study demonstrates the feasibility of genotype-driven dosing of
tamoxifen for the substantial proportion of women who are interme-
diate metabolizers of the agent. Like others, we noted good correlation
between baseline plasma endoxifen concentrations and CYP2D6 ge-
notype. Our data suggest that doubling the dose of tamoxifen can raise
endoxifen concentrations in IM patients to the extent that the differ-
ences between EM and IM concentrations are no longer statistically
significant. While the endoxifen concentrations in PM patients also
increased, these increases were more modest than in the IM group,
and the final endoxifen concentration in these patients remained
significantly lower than in the other two groups. That the endoxifen
concentrations increased at all in PM patients is interesting, and may
reflect metabolism by other enzymes in the pathway. This question
will be addressed in a recently completed 500 patient expansion study.
These data address one aspect of the clinical utility of genotype-
guided dosing, namely that in the large group of patients who possess
intermediate metabolizing genes, it is possible to at least partly com-
pensate for inherited inadequate metabolism by changing the dose.
We found that the 40 mg tamoxifen dose is safe, US Food and Drug
Administration approved, and efficacious. If further studies of tamox-
ifen dosing are pursued, far higher doses may be considered,43 how-
ever, extrapolating from our data in the PM group and assuming a
linear relationship, increasing the endoxifen concentrations in the PM
group to those in the EM group may take a dose more than 100 mg to
achieve. It should be noted that at high tamoxifen doses, an increase in
retinopathy has been documented.44 However, this study was not
designed to demonstrate that actively managing endoxifen concentra-
tions will improve outcomes. It is not clear that CYP2D6 by itself can
predict outcomes; two recent studies in postmenopausal women did
not find an association.35,36 Tamoxifen and the non-CYP2D6 metab-
olites produce greater than 99% ER saturation in postmenopausal
women45 possibly making endoxifen activity less relevant. Whether
study of additional enzymes or a focus on premenopausal women will
demonstrate relevance for outcome is yet unknown. While some
initial studies did demonstrate worse outcomes (DFS or time to pro-
gression) for those who are CYP2D6 IM or PM on tamoxifen com-
pared to EM,20-33 this finding has never been consistent.12-19,35,36
Evidence that supports the effect of tamoxifen metabolism on breast
cancer outcomes comes from drug-interaction studies that demon-
strate concurrent use of medications (especially selective-serotonin
reuptake inhibitors) that inhibit CYP2D6 reduce DFS,24,27,33,34 al-
though this is also somewhat controversial.35 Given that the impact of
these CYP2D6/drug interactions is to decrease endoxifen concentra-
tions, our findings may have implications for patients on CYP2D6-
interacting drugs who cannot change drugs and are appropriate for
tamoxifen; however the ability to alter endoxifen concentrations in the
setting of CYP2D6 inhibitors is not established here.
Our study is one of two tamoxifen CYP2D6 studies15 that
included a significant percentage of African American patients. We
found that the allele frequency of reduced metabolism alleles was
greater in African Americans than in other patients with the IM
allele *17 being common in African Americans. This may partially
explain the disproportionally worse outcome suffered by pre-
menopausal African American women with breast cancer.46
We found no association between endoxifen concentrations and
hot flashes, nor between genotype group or dose of tamoxifen and hot
flashes. However, a study size of 500 would be required to identify a
10% difference in hot flash scores, larger than the study presentedhere.
Although some have suggested that endocrine symptoms, especially

























Fig 4. Median endoxifen concentration by genotype group for the generalized
estimating equation shown to address the pattern of change over time for the
three genotype groups. The intermediate metabolizers (IM) group had a signifi-
cant increase in endoxifen concentration when compared to the extensive
metabolizers (EM) group (P  .0062). The poor metabolizers (PM) group also had
a significant pattern of change (P  .0035) when compared to the EM group.
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we would recommend caution until further data becomes available in
using vasomotor symptoms to determine the efficacy of tamoxifen. In
general, physicians should be cautious when discussing emerging
genomic markers with patients. In 2009, a community-based survey
suggested that nearly one in three oncologists had ordered CYP2D6
genotyping.49 Our data suggest that participants in pharmacogenomic
trials have a high expectation of benefit despite emphasis in informed
consent documents of the scientific purpose of the research and the
uncertainty of any direct benefit.50
Aclear limitationof this studyis the lackofclinicaloutcomedata.To
demonstrate a clinical impact of genotype-driven dosing of tamoxifen, a
prospective, randomized controlled trial of different doses of tamoxifen
forIMsandpossiblyPMswithclinicalendpointswouldbeneeded.While
ourstudywaspredicatedon genotype-driven dosing, trying to dose to a
particular endoxifen concentration might be more efficacious. How-
ever, the precise clinically relevant endoxifen concentration is un-
known, and efficacy may not be solely mediated via endoxifen. While
genotype-driven therapy may impact outcome, the impact is likely in
the increase of the active metabolite concentration and thus in the end,
the directed therapy may be the endoxifen concentration.
While the majority of EM patients had no notable change in
endoxifen concentration, eight patients had a marked decrease and
eight had PM-like concentrations that are poorly understood. Adher-
ence was self-reported, which has clear limitations,51 and up to 68% of
tamoxifen patients are nonadherent.52 Also, large increases were seen
in about one third of the IM patients, while marginal increases were
seen in others, a phenomenon that is also poorly understood. Stan-
dard curves and quality controls were run with each sample batch with
very good agreement between these runs. Although we did not run an
intrapatient assay for each sample, the assay is robust and in a subset of
samples the results showed low intrasample variability. To obtain a
complete picture of tamoxifen metabolism and for individualized
dosing to be relevant, one needs to examine the effect of alterations in
other genes that metabolize tamoxifen (or eliminate endoxifen such as
the UDP-glucuronosyltranferases) as these genes may also be impact-
ing endoxifen concentrations, and may be responsible for the low
endoxifen concentrations seen in some EM patients.
It is possible that the lack of statistical significance in endoxifen
concentration between the IM group at 40 mg and the EM group is
due to the sample size. This study had 80% power to detect a 40%
difference in endoxifen concentrations, making the lack of an ade-
quate sample size an unlikely explanation for this finding. The expan-
sion study mentioned above will have power higher than 99%.
Endoxifen is a highly active tamoxifen metabolite, and this study
suggests that pharmacogenomic knowledge can be successfully used
to manage drug concentrations. CYP2D6 testing does not currently
meet evidence for clinical use in that endoxifen concentration may not
affect outcome, or it may matter in some as-yet unidentified subsets
but not in others.
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